Sentences with word «sofosbuvir»

Since then, Gilead has run three additional studies of sofosbuvir paired with a different drug, ledipasvir.

Dr. Jacobson adds that future clinical studies will continue to define the optimal length of treatment duration for patients with genotype 3, and that other antiviral drugs in combination with sofosbuvir might shorten the duration of treatment needed to maximize the rates of response.

Taylor's research team, which included the Harvard Law School Center for Health Law and Policy Innovation, Treatment Action Group, Kirby Institute of Australia, and Brown University, found that most Medicaid coverage restrictions for sofosbuvir violate federal Medicaid law, which requires states to cover drugs consistent with their U.S. Food and Drug Administration (FDA) labels.

Gilead has a second hepatitis C combination therapy using sofosbuvir in late - stage development.

301 chronically infected adults were treated with the ravidasvir / sofosbuvir combination for 12 weeks for patients without cirrhosis of the liver, and for 24 weeks for those with compensated cirrhosis.

Taylor's team of researchers examined Medicaid policies for hepatitis C virus treatment using sofosbuvir, more commonly known as Solvadi, and found that most should change policy to improve access to the treatment.

The current standard of care for HCV genotype 3 is the nucleotide polymerase inhibitor sofosbuvir with weight - based RBV for 24 weeks.

The FDA approved sofosbuvir in late 2013 as a treatment for hepatitis C in combination with ribavirin.

The drug sofosbuvir works by interfering with the ability of the hepatitis C virus to replicate.

This clinical trial study, called FUSION, was designed to test sofosbuvir and ribavirin in hepatitis C patients with genotype 2 or 3 who had failed interferon therapy.

«In distinct contrast to the situation in the U.S., Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended two highly effective sofosbuvir - based regimens for Pharmaceutical Benefits Scheme (PBS) listing, without drug use or disease stage - related restrictions,» said co-author and professor Greg Dore of the Kirby Institute.

In September 2017, the government of Malaysia issued a «government - use» license on sofosbuvir patents to allow 400,000 people living with hepatitis C in Malaysia to access generic HCV regimens in public hospitals.

«Given the absence to date of alternative therapies for patients with genotype 2 or 3 who have failed interferon therapy or for whom it is not an option, treatment with the new sofosbuvir regimen offers a vast improvement,» Dr. Jacobson says.

The team investigated an antiviral drug called sofosbuvir, approved and marketed under the brand name Sovaldi to treat and cure hepatitis C infections.

Notably pricey members of the influential list include sofosbuvir for HCV and the antileukemia drug Gleevec.

In March, Gilead announced a deal with Egypt to provide sofosbuvir at $ 900 for a 12 - week course.

The most common restrictions fall into three categories: 1) The level of fibrosis (i.e., scarring of the liver); 2) substance use and abstinence from alcohol / drug use together with toxicology screening; and 3) provider limitations, which limit the physicians allowed to prescribe sofosbuvir.

Sofosbuvir belongs to a class of directly acting anti-viral (DAA) drugs known as nucleotide analogue polymerase inhibitors, which are designed to block an enzyme the hepatitis C virus needs to copy itself.

The findings showed that extended use of sofosbuvir resulted in a higher cure rate in both genotypes, but that the difference seen in genotype 3 was highly significant.

In our analysis, we found that most states with known sofosbuvir Medicaid reimbursement requirements impose undue restrictions on eligible recipients.»

Data extracted included whether sofosbuvir was covered and coverage criteria based on liver disease stage; HIV coinfection; prescriber type; and drug / alcohol use.

The recent release of drugs such as sofosbuvir has marked the first successful and nontoxic treatments for hepatitis C — treatments which came directly from the work of Bartenschlager, Rice, and Sofia.

This is one of the first real - life studies looking into sofosbuvir / daclatasvir combinations and has demonstrated that this is a good therapeutic option for these patients.

The new formulation was named sofosbuvir in Sofia's honor; the company was purchased, in 2011, by Gilead for $ 11 billion.

At the FDA meeting to review sofosbuvir for approval, Sofia listened to testimony from a patient who had been cured by the new drugs at practically the last minute.

During sofosbuvir's development, they had studied other drugs that inhibited different viral proteins and that might eliminate the need for continued use of interferon and ribavirin.

In Egypt, which has the world's highest rate of hepatitis C, sofosbuvir costs $ 300 for a 28 - day supply.

In subsequent tests using an immunodeficient mouse model infected by Zika, intravenous injections of sofosbuvir significantly reduced viral loads in blood serum compared to a placebo group.

In tests using human neural progenitor cells (NPCs)-- self - renewing, multipotent cells that generate neurons and other brain cell types — the scientists found that exposure to sofosbuvir not only rescued dying NPCs infected with the Zika virus, but restored gene expression linked to their antiviral response.

The drug works by inhibiting replication of the hepatitis C virus; researchers noted that both hepatitis C and Zika belong to the same viral family and bore strong structural similarities that could make sofosbuvir effective against the latter.

As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians» discretion for up to 48 weeks.

Published in Nature Scientific Reports, the study showed sofosbuvir (Sovaldi), a drug made by Gilead to treat hepatitis C, could also be effective against Zika.

Results presented today at The International Liver Congress ™ 2015 demonstrate that hepatitis C (HCV)- infected genotype - 3 (GT - 3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

Results from three Phase III clinical trials (ION - 1, ION - 2 and ION - 3) evaluating the investigational once - daily fixed - dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and the NS5A inhibitor ledipasvir (LDV) 90 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014.

The U.S. Food and Drug Administration (FDA) has not yet approved sofosbuvir.

«Daclatasvir - sofosbuvir combination highly effective and well tolerated in patients with hepatitis C.» ScienceDaily.

For this study, the team will test Sofosbuvir, a new drug, and Ribavirin, which is used in the treatment with interferon.

His work on sofosbuvir was performed while he was at the Princeton - N.J. - based company Pharmasset, which later was acquired by Gilead Sciences.

«The new sofosbuvir therapy offers a much - needed alternative to standard therapy with interferon, which can cause significant side effects for hepatitis C patients,» says the study's lead investigator, Dr. Ira Jacobson, chief of the Division of Gastroenterology and Hepatology and Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College.

The drug, called sofosbuvir, offers more effective treatment for most patients studied in a Phase 3 clinical trial who had no other treatment options, report researchers in The New England Journal of Medicine.

«We are achieving the same or higher cure rates in many patients with sofosbuvir, compared to interferon, and we are doing it in half the time with a drug that has a remarkable safety profile.»

The Federal Court of Appeal has not squarely addressed the discrete disclosure issue since the SCC arguably «reinvigorated» the debate in Pfizer v Novopharm («Viagra SCC»)[3], but may address the matter over the next year in Idenix's pending appeal regarding the hepatitis drug sofosbuvir.

Meanwhile, the Initiative for Medicines, Access & Knowledge, a non-profit group in New York, has filed a lawsuit with India's patent office seeking to prevent Gilead from receiving a patent for sofosbuvir.

«Sofosbuvir in combination with ribavirin and with and without peginterferon have never been directly compared before to determine sustained virologic response 12 weeks after treatment.

Using sofosbuvir - ledipasvir, which is sold as Harvoni, and is one several new drugs for hepatitis C, researchers compared the costs of treating patients at all stages of fibrosis, zero through four, with the cost of waiting until stages three or four, which is when some patients are usually treated.

It combines the generic chemical form of Gilead's brand name hepatitis C treatment Sovaldi (sofosbuvir) and Pharco's experimental ravidasvir.

Gilead Sciences» first offering, Sovaldi (sofosbuvir), was approved in the U.S. in December.

This study highlights that sofosbuvir with ribavirin and peginterferon should be considered for interferon - eligible GT - 3 patients, particularly for those with cirrhosis and / or prior treatment failure,» said Graham Foster, Professor of Hepatology, Queen Marys University of London, UK.

It has confirmed that 24 weeks is the optimal duration for a sofosbuvir and ribavirin combination in GT - 3 patients, whilst also finding that sofosbuvir and ribavirin with peginterferon for 12 weeks resulted in the highest SVR12 rates observed to date in a Phase 3 study,» said Professor Tom Hemming Karlsen, Scientific Committee Member, European Association for the Study of the Liver (EASL).